Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Breast Cancer Epigenetics Study Reveals Potential Drug Targets

Page View:

Cell lineages that culminate in mammary gland development may also lead to breast cancer. Although these lineages, as well as the stem cells and progenitor cells they comprise, have been subjected to extensive study, the perturbations of these lineages that increase the risk of breast cancer have remained obscure, frustrating the search for chemoprevention drugs.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

Consequently, scientists at the Princess Margaret Cancer Center in Toronto closely looked at mammary cell lineages. These scientists have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone.

Breast Cancer.jpg

This discovery was detailed in a paper (“Mammary Molecular Portraits Reveal Lineage-Specific Features and Progenitor Cell Vulnerabilities”) that appeared in the Journal of Cell Biology. This paper, which describes the comprehensive profiling of the epigenomes, transcriptomes, and proteomes of cells isolated from mice and women and high risk of developing breast cancer, suggests that inhibiting epigenetic proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.

“Currently, there are no standard-of-care preventative interventions for women at high risk of breast cancer,” said Rama Khokha, Ph.D., a senior scientist at Princess Margaret Cancer Center and a professor of medical biophysics at the University of Toronto. “Although it is becoming increasingly clear that stem and progenitor cells underlie cancer development, we lack strategies to target these cells for chemoprevention.”

To learn more about these progenitor cells and identify any vulnerabilities that could potentially be exploited to prevent the development of breast cancer, Dr. Khokha and colleagues isolated cells from the mammary glands of mice and examined how they changed in response to progesterone. The researchers had previously measured all of the RNA molecules produced by mammary gland cells. Now they quantified all of the cells’ proteins and assessed the cells’ epigenomes – the various chemical modifications to a cell’s chromosomes that help determine which genes are turned on and off.

“We define systems-level relationships between chromatin – DNA-RNA – protein states, identify lineage-specific DNA methylation of transcription factor binding sites, and pinpoint proteins underlying progesterone responsiveness,” wrote the authors of the JCB article. “Comparative proteomics of estrogen and progesterone receptor–positive and –negative cell populations, extensive target validation, and drug testing leads to the discovery of stem and progenitor cell vulnerabilities.”

Related Articles:

Protein in Breast Cancer Found to Be Essential for Metastasis

Cancer Metabolism Link with Breast Cancer Oncogene

DNA Mapping Finds 110 Genes Linked to Breast Cancer

This global overview of mammary gland cells revealed that in response to progesterone, progenitor cells – particularly luminal progenitor cells – upregulate many of the epigenetic regulatory proteins responsible for modifying the cells’ chromosomes.

Mammary glands contain two types of cells, basal and luminal, that arise from specialized stem or progenitor cells. During pregnancy or the menstrual cycle, progesterone induces basal and luminal progenitor cell numbers to expand and drive mammary gland formation. But mammary gland progenitors may also give rise to cancer. Progesterone exposure and stem cell proliferation have been linked to the development of breast cancer, and the number of progenitor cells is often elevated in women carrying mutations in BRCA1 or other genes that put them at a high risk of developing the disease.

After discovering “stem and progenitor cell vulnerabilities,” Dr. Khokha and colleagues tested multiple epigenetic inhibitors. “We thought,” Dr. Khoka explained, “that drugs that inhibit epigenetic regulatory proteins might suppress the proliferation of stem and progenitor cells in response to progesterone.”

“Top epigenetic drugs exert cytostatic effects; prevent adult mammary cell expansion, clonogenicity, and mammopoiesis; and deplete stem cell frequency,” the JBC paper added. “Select drugs also abrogate human breast progenitor cell activity in normal and high-risk patient samples.”

The researchers tested multiple epigenetic inhibitors, many of which are already approved for human use by the FDA. Several of these drugs inhibited the proliferation of mammary gland progenitor cells and decreased their total number in mice. One, a drug called decitabine that inhibits DNA methyltransferase enzymes and is approved to treat myelodysplastic syndrome, delayed the formation of tumors in breast cancer–prone rodents.

Khokha and colleagues then tested the effects of epigenetic inhibitors on mammary gland progenitor cells isolated from women at high risk of developing breast cancer. Progenitor cells from patients with BRCA1 mutations were particularly vulnerable to epigenetic inhibitors, including decitabine. Decitabine also suppressed the activity of progenitor cells in patients with mutations in the BRCA2 gene.

“This demonstrates that the dependency of progenitor cells on specific epigenetic proteins is conserved between mice and humans and highlights the potential of epigenetic therapies to target these important cell types in the human breast as a form of chemoprevention,” concluded Dr. Khokha.

Relevant newsRelevant news